Eli Lilly receives full FDA approval for selpercatinib in solid tumors

Eli Lilly and Company said on Tuesday that the US Food and Drug Administration granted full, traditional approval for selpercatinib for use in solid tumors. The approval marks an FDA decision that Lilly framed as a step beyond earlier review pathways, positioning the drug for broader use in routine clinical practice rather than under accelerated or conditional frameworks.

Selpercatinib is Lilly’s targeted therapy designed to inhibit a specific cancer-driving pathway associated with certain tumor types. In oncology, targeted drugs are typically used when tumors carry a relevant genetic feature, allowing clinicians to match therapy to the biology of the disease.

Lilly did not provide additional details in the published report beyond the existence of the FDA approval and its application to solid tumors. The company did not, in the referenced posting, specify the exact tumor subtype(s), line of therapy, companion diagnostic requirements, or the size and composition of the underlying clinical program that supported the FDA decision.

The news arrives as regulators continue to refine when and how targeted oncology medicines advance to full approval. In many cases, companies start with accelerated approval while confirmatory evidence is gathered, then later seek traditional approval once the full evidence package satisfies the FDA’s criteria for benefit and safety.

For Lilly, full approval can be operationally important. A “traditional” approval generally indicates that the FDA has accepted the totality of evidence for the labeled population, which can affect clinician adoption, formulary access, and how the indication is marketed and supported in post-market settings.

Investors and industry watchers will likely focus on how the solid-tumor indication is defined in Lilly’s labeling and what differentiates it from any prior authorization. Without those particulars in the reported announcement, it remains unclear whether the approval covers a broad solid-tumor basket or a narrower set of tumor types.

It is also not clear from the report whether the FDA action ties to new efficacy data, additional safety follow-up, or simply completion of confirmatory study requirements. The lack of trial-level detail means the market impact could depend heavily on the final label wording, which determines how many patients are eligible to receive the medicine.